All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub
Brought to you by Scientific Education Support

The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

APLAR Congress 2022

Share:

Dec 7, 2022

X post image

10 Dec 2022

We covered #APLAR22 virtually!

We hope you enjoyed following our live updates and congress coverage.

Keep an eye on our socials for post-congress key points and insights.

#medicalcongress #psoriasis #rheumatology

View on 

X post image

8 Dec 2022

CONGRESS #APLAR22 | @AlexisOgdie discussed whether treating #psoriasis aggressively impacts #psoriaticarthritis development. Obs data seems to show that biologic treated pts had a higher PsA risk, but this may actually be due to differing access to rheum – prosp trials are needed

View on 

X post image

8 Dec 2022

CONGRESS #APLAR22 | Katy Leung discussed the composite for PsA project aims and working group delphi exercise, & concluded with the ongoing work being done on the shortlisted composites (domain match/feasibility, syst rev & meta-analysis). #psoriaticarthritis

View on 

X post image

8 Dec 2022

CONGRESS #APLAR22 | Muhammad Haroon discussed MetS & #psoriaticarthritis, highlighting links between obesity & #psoriasis/PsA onset, & management, also between CVD & pso/PsA. MetS linked to pso & PsA: ^ coronary plaque burden in PsA independent of MetS, but linked to PsA severity

View on 

X post image

8 Dec 2022

CONGRESS #APLAR22 | Thomas SY Chan @hkumed shared clinical aspect of stem cell transplant in rheumatic disease. Auto-HSCT can be a curative strategy in some rheumatological diseases. Novel treatments are being developed to reduce TRM & preserve efficacy #PsA #psoriaticarthritis

View on 

X post image

8 Dec 2022

CONGRESS #APLAR22 | Kichul Shin @SNUnow presented on Derm-Rheum collaborations in the holistic management of #psoriaticarthritis, showing different combined derm-rheum clinic models, and how this is evolving, suggesting that sharing of learnings on therapeutics is important

View on 

X post image

8 Dec 2022

CONGRESS #APLAR22 | Ka Wing Gavin Lee discussed ultrasound (US) in #psoriaticarthritis
-many MSK features can be assessed by US
-subclinical disease detection
-earlier diagnosis
-improved diagnostic accuracy
-disease differentiation
-correlation with erosive joint damage

View on 

X post image

7 Dec 2022

CONGRESS #APLAR22 | Georg Schett at the University of Erlangen-Nuremberg discussed disease mechanisms that influence the treatment of PSA/SpA and explained how genetic-based inflammation threshold, cardiometabolic factors & cytokinins affect #PsA #rheumatology #psoriaticarthritis

View on 

X post image

7 Dec 2022

CONGRESS #APLAR22 | Yoshiya Tanaka shares the key results from the BE COMPLETE ph III trial with bimekizumab in patients with inadequate response to TNH-inh. Responses translated rapidly into an improvement in signs and symptoms of PsA. #rheumatology #psoriaticarthritis

View on 

X post image

6 Dec 2022

#APLAR22 starts today!

The Psoriasis and Psoriatic Arthritis Hub is covering APLAR virtually.

Keep an eye on our Twitter page for live updates, key insights, and interview coverage.

#medicalcongress #psoriasis #rheumatology

View on 

X post image

6 Dec 2022

The Psoriasis and Psoriatic Arthritis Hub will be covering #APLAR22!

🗓 Date: Dec 6–9
📍 Location: Hong Kong and virtual

Leading experts will share top research in rheumatology.

Keep an eye on our Twitter page for live coverage from our virtual attendance.

View on 

 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

APLAR 2022Asia Pacific League of Associations for Rheumatology

Newsletter

Subscribe to get the best content delivered to your inbox